Cargando…
Absorption, Metabolism, and Excretion of [(14)C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity
BACKGROUND AND OBJECTIVE: Tolebrutinib is a covalent inhibitor of Bruton’s tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are thought to be major drivers of inflammation in multiple sclerosis. This excretion balance and metabolism study evaluated t...
Autores principales: | Nicolas, Olivier, Moliner, Patricia, Soubayrol, Patrick, Vitse, Olivier, Roy, Sebastien, Cabanis, Marie-José, Turner, Tim, Klieber, Sylvie, Muccio, Stephane, Arabeyre, Catherine, Brun, Priscilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480245/ https://www.ncbi.nlm.nih.gov/pubmed/37642857 http://dx.doi.org/10.1007/s40261-023-01296-1 |
Ejemplares similares
-
Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug
por: Klieber, Sylvie, et al.
Publicado: (2014) -
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)
por: Owens, Timothy D., et al.
Publicado: (2021) -
Absorption and Excretion of Antipyrine
Publicado: (1888) -
Absorption, distribution, metabolism, and excretion of [(14)C]‐dasotraline in humans
por: Chen, Yu‐Luan, et al.
Publicado: (2016) -
Absorption, metabolism and excretion of [(14)C]pomalidomide in humans following oral administration
por: Hoffmann, Matthew, et al.
Publicado: (2012)